Very late stent thrombosis lacking findings of the typical causes on optical coherence tomography in a patient with SARS-CoV-2.
Coronavirus disease 2019
Drug-eluting stent
Dual antiplatelet therapy
Journal
Journal of cardiology cases
ISSN: 1878-5409
Titre abrégé: J Cardiol Cases
Pays: Japan
ID NLM: 101549579
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
03
03
2022
revised:
18
04
2022
accepted:
22
04
2022
pubmed:
17
5
2022
medline:
17
5
2022
entrez:
16
5
2022
Statut:
ppublish
Résumé
A 50-year-old male was admitted to our hospital with sudden-onset chest pain. He was a current smoker with severe obesity and diabetes. He had a history of drug-eluting stent (DES) implantation in the left anterior descending artery (LAD) and had continuously taken clopidogrel. Eight days prior to admission, polymerase chain reaction testing confirmed that he was positive for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Emergent coronary angiography revealed total occlusion of previously implanted DES in LAD. Optical coherence tomography (OCT) images demonstrated the presence of large white thrombus within the well-expanded DES with homogenous neointima. There were no findings of malapposed strut, uncovered strut, intimal disruption, or neoatherosclerosis through the stented segment. Subsequent dilation using a drug-coated balloon successfully restored coronary flow in LAD. We experienced a case of very late stent thrombosis without findings of the typical causes on OCT images nor discontinuation of antiplatelet therapy in a patient with SARS-CoV-2. The present case suggests that SARS-CoV-2 infection may induce stent thrombosis irrespective of the presence of known causes and the status of antiplatelet therapy. The underlying causes of very late stent thrombosis (VLST) include strut malapposition, neoatherosclerosis, uncovered struts and stent underexpansion in addition to inadequate discontinuation of antiplatelet therapy and/or systemic hyper coagulable state. The present case of VLST lacking those factors suggests the enhanced hyper thrombogenicity irrespective of the presence of known causes and the status of antiplatelet therapy in patients with severe acute respiratory syndrome coronavirus type 2.
Identifiants
pubmed: 35572350
doi: 10.1016/j.jccase.2022.04.011
pii: S1878-5409(22)00081-0
pmc: PMC9091356
doi:
Types de publication
Case Reports
Langues
eng
Pagination
197-199Informations de copyright
© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. All rights reserved.
Déclaration de conflit d'intérêts
None.